Antigen Delivery to Macrophages Using Liposomal Nanoparticles Targeting Sialoadhesin/CD169
暂无分享,去创建一个
James C. Paulson | N. Kawasaki | Corwin M. Nycholat | J. Paulson | P. Crocker | W. Chen | Paul R. Crocker | Shoufa Han | Weihsu C. Chen | Shoufa Han | Norihito Kawasaki | Julie Pilotte | J. Pilotte
[1] K. Marr,et al. Methods of in vitro macrophage maturation confer variable inflammatory responses in association with altered expression of cell surface dectin-1. , 2008, Journal of immunological methods.
[2] E. Jones,et al. Structure-guided design of sialic acid-based Siglec inhibitors and crystallographic analysis in complex with sialoadhesin. , 2003, Structure.
[3] F. Batista,et al. B cells acquire particulate antigen in a macrophage-rich area at the boundary between the follicle and the subcapsular sinus of the lymph node. , 2007, Immunity.
[4] G. Besra,et al. CD169+ MACROPHAGES PRESENT LIPID ANTIGENS TO MEDIATE EARLY ACTIVATION OF INVARIANT NKT CELLS IN LYMPH NODES , 2010, Nature Immunology.
[5] J. Irache,et al. Mannose-targeted systems for the delivery of therapeutics. , 2008, Expert opinion on drug delivery.
[6] Maureen E. Taylor,et al. Structural insights into what glycan arrays tell us about how glycan-binding proteins interact with their ligands , 2009, Glycobiology.
[7] Hiroaki Tateno,et al. Mouse Siglec-F and human Siglec-8 are functionally convergent paralogs that are selectively expressed on eosinophils and recognize 6'-sulfo-sialyl Lewis X as a preferred glycan ligand. , 2005, Glycobiology.
[8] T. Sparwasser,et al. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation. , 2009, Molecular immunology.
[9] CD22 Is a Recycling Receptor That Can Shuttle Cargo between the Cell Surface and Endosomal Compartments of B Cells , 2011, The Journal of Immunology.
[10] J. Garcia-Vallejo,et al. Glycan modification of the tumor antigen gp100 targets DC‐SIGN to enhance dendritic cell induced antigen presentation to T cells , 2008, International journal of cancer.
[11] Nan Li,et al. Cloning and Characterization of Siglec-10, a Novel Sialic Acid Binding Member of the Ig Superfamily, from Human Dendritic Cells* , 2001, The Journal of Biological Chemistry.
[12] Chuan Wu,et al. Sialoadhesin-Positive Macrophages Bind Regulatory T Cells, Negatively Controlling Their Expansion and Autoimmune Disease Progression1 , 2009, The Journal of Immunology.
[13] T. Winkler,et al. Siglec-G is a B1 cell–inhibitory receptor that controls expansion and calcium signaling of the B1 cell population , 2007, Nature Immunology.
[14] W. Hubbard,et al. Inhibition of FcepsilonRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement. , 2008, The Journal of allergy and clinical immunology.
[15] M. Litjens,et al. Design of neo‐glycoconjugates that target the mannose receptor and enhance TLR‐independent cross‐presentation and Th1 polarization , 2011, European journal of immunology.
[16] James C Paulson,et al. In vivo targeting of B-cell lymphoma with glycan ligands of CD22. , 2010, Blood.
[17] N. Damle,et al. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia , 2007, Leukemia.
[18] J. Domínguez,et al. Delivery of antigen to sialoadhesin or CD163 improves the specific immune response in pigs. , 2011, Vaccine.
[19] Y. Liu,et al. Siglecg Limits the Size of B1a B Cell Lineage by Down-Regulating NFκB Activation , 2007, PloS one.
[20] G. V. van Dooren,et al. Dynamics of T cell, antigen-presenting cell, and pathogen interactions during recall responses in the lymph node. , 2009, Immunity.
[21] Jian Ni,et al. Siglec-8 , 2000, The Journal of Biological Chemistry.
[22] Kenneth G. C. Smith,et al. CD22: an inhibitory enigma , 2008, Immunology.
[23] H. Nauwynck,et al. Porcine Arterivirus Attachment to the Macrophage-Specific Receptor Sialoadhesin Is Dependent on the Sialic Acid-Binding Activity of the N-Terminal Immunoglobulin Domain of Sialoadhesin , 2007, Journal of Virology.
[24] P. Crocker,et al. Siglecs as positive and negative regulators of the immune system. , 2008, Biochemical Society transactions.
[25] H. Nauwynck,et al. IFN-alpha treatment enhances porcine Arterivirus infection of monocytes via upregulation of the porcine Arterivirus receptor sialoadhesin. , 2007, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[26] J. Paulson,et al. Sialoside analogue arrays for rapid identification of high affinity siglec ligands. , 2008, Journal of the American Chemical Society.
[27] Jay K. Nathan,et al. High-Affinity Ligand Probes of CD22 Overcome the Threshold Set by cis Ligands to Allow for Binding, Endocytosis, and Killing of B Cells1 , 2006, The Journal of Immunology.
[28] H. Nauwynck,et al. Sialoadhesin and CD163 join forces during entry of the porcine reproductive and respiratory syndrome virus. , 2008, The Journal of general virology.
[29] James C Paulson,et al. Siglecs as targets for therapy in immune-cell-mediated disease. , 2009, Trends in pharmacological sciences.
[30] P. Crocker,et al. Recognition of sialylated meningococcal lipopolysaccharide by siglecs expressed on myeloid cells leads to enhanced bacterial uptake , 2003, Molecular Microbiology.
[31] Y. Ikehara,et al. Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[32] Y. Barenholz,et al. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. , 1993, Biochimica et biophysica acta.
[33] Jacob P. Brady,et al. Prolectin, a Glycan-binding Receptor on Dividing B Cells in Germinal Centers , 2009, The Journal of Biological Chemistry.
[34] H. Favoreel,et al. Porcine Sialoadhesin (CD169/Siglec-1) Is an Endocytic Receptor that Allows Targeted Delivery of Toxins and Antigens to Macrophages , 2011, PloS one.
[35] A. Suzuki,et al. Lymph node macrophages, but not spleen macrophages, express high levels of unmasked sialoadhesin: implication for the adhesive properties of macrophages in vivo. , 2002, Glycobiology.
[36] Yang Liu,et al. CD24 and Siglec-10 Selectively Repress Tissue Damage–Induced Immune Responses , 2009, Science.
[37] D. Jackson,et al. Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflammatory macrophage populations. , 2001, Blood.
[38] Yasunobu Miyake,et al. CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. , 2011, Immunity.
[39] N. Hacohen,et al. Carbohydrate‐Mediated Targeting of Antigen to Dendritic Cells Leads to Enhanced Presentation of Antigen to T Cells , 2008, Chembiochem : a European journal of chemical biology.
[40] H. Nakanishi,et al. Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells. , 2008, Cancer letters.
[41] N. Kawasaki,et al. CD22 Regulates Adaptive and Innate Immune Responses of B Cells , 2010, Journal of Innate Immunity.
[42] L. Pulliam,et al. Sialoadhesin Expressed on IFN-Induced Monocytes Binds HIV-1 and Enhances Infectivity , 2008, PloS one.
[43] R. Brossmer,et al. The Ligand-binding Domain of CD22 Is Needed for Inhibition of the B Cell Receptor Signal, as Demonstrated by a Novel Human CD22-specific Inhibitor Compound , 2002, The Journal of experimental medicine.
[44] V. Apostolopoulos,et al. Mannan‐mediated gene delivery for cancer immunotherapy , 2007, Immunology.
[45] J. Paulson,et al. Multivalent ligands for siglecs. , 2010, Methods in enzymology.
[46] N. Bovin,et al. Eosinophil-Selective Binding and Proapoptotic Effect in Vitro of a Synthetic Siglec-8 Ligand, Polymeric 6′-Sulfated Sialyl Lewis X , 2009, Journal of Pharmacology and Experimental Therapeutics.
[47] Ajit Varki,et al. Siglecs and their roles in the immune system , 2007, Nature Reviews Immunology.